1. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma
- Author
-
Ryota Shirai, Tomoo Osumi, Dai Keino, Kazuhiko Nakabayashi, Toru Uchiyama, Masahiro Sekiguchi, Mitsuteru Hiwatari, Masanori Yoshida, Kaoru Yoshida, Yuji Yamada, Daisuke Tomizawa, Seido Takae, Nobutaka Kiyokawa, Kimikazu Matsumoto, Takako Yoshioka, Kenichiro Hata, Toshinori Hori, Nao Suzuki, and Motohiro Kato
- Subjects
Hematology - Abstract
Minimal residual disease (MRD) is usually defined as the small number of cancer cells that remain in the body after treatment. The clinical significance of MRD kinetics is well recognized in treatment of hematologic malignancies, particularly acute lymphoblastic leukemia (ALL). Real time quantitative PCR targeting immunoglobulin (Ig) or T-cell receptor (TCR) rearrangement (PCR-MRD), as well as multiparametric flow cytometric analysis targeting antigen expression, are widely used in MRD detection. In this study, we devised an alternative method to detect MRD using droplet digital PCR (ddPCR), targeting somatic single nucleotide variants (SNVs). This ddPCR-based method (ddPCR-MRD) had sensitivity up to 1E-4. We assessed ddPCR-MRD at 26 time points from eight T-ALL patients, and compared it to the results of PCR-MRD. Almost all results were concordant between the two methods, but ddPCR-MRD detected micro-residual disease that was missed by PCR-MRD in one patient. We also measured MRD in stored ovarian tissue of four pediatric cancer patients, and detected 1E-2 of submicroscopic infiltration. Considering the universality of ddPCR-MRD, the methods can be used as a complement for not only ALL, but also other malignant diseases regardless of tumor-specific Ig/TCR or surface antigen patterns.
- Published
- 2023
- Full Text
- View/download PDF